Pier Paolo Pandolfi

Pier Paolo Pandolfi's AcademicInfluence.com Rankings

Pier Paolo Pandolfi

Biology

#600

World Rank

#1058

Historical Rank

Genetics

#101

World Rank

#136

Historical Rank

biology Degrees

Download Badge

Biology

Pier Paolo Pandolfi's Degrees

Doctorate Medicine University of Perugia
PhD Molecular Biology University of Perugia

Why Is Pier Paolo Pandolfi Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Pier Paolo Pandolfi is an Italian doctor, geneticist, molecular biologist, and cancer researcher. Early life and education Originally from Rome, Italy, Pandolfi studied medicine at the University of Perugia in Umbria in central Italy, where he began his research into acute promyelocytic leukemia. He received his MD in 1989, his Ph.D. in 1995, and did postgraduate work at the Royal Postgraduate Medical School.

(See a Problem?)

Pier Paolo Pandolfi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? (2011) (5387)
The multilayered complexity of ceRNA crosstalk and competition (2014) (2894)
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis (2005) (1923)
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology (2010) (1917)
The functions and regulation of the PTEN tumour suppressor (2012) (1740)
The p66shc adaptor protein controls oxidative stress response and life span in mammals (1999) (1725)
Pten is essential for embryonic development and tumour suppression (1998) (1550)
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies (1998) (1547)
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. (2008) (1410)
Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis (2005) (1272)
The Multiple Roles of PTEN in Tumor Suppression (2000) (1237)
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. (1998) (1231)
Tenets of PTEN Tumor Suppression (2008) (1034)
Crystal Structure of the PTEN Tumor Suppressor Implications for Its Phosphoinositide Phosphatase Activity and Membrane Association (1999) (1032)
Does the ribosome translate cancer? (2003) (945)
Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity (2007) (943)
Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs (2011) (927)
Essential role of Plzf in maintenance of spermatogonial stem cells (2004) (879)
Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies (2007) (871)
Cancer metabolism: fatty acid oxidation in the limelight (2013) (867)
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation (1997) (866)
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras (2000) (865)
The PTEN–PI3K pathway: of feedbacks and cross-talks (2008) (836)
Nucleophosmin and cancer (2006) (807)
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. (2011) (733)
SUMO Modification of Huntingtin and Huntington's Disease Pathology (2004) (728)
Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression (2007) (716)
Pten Dose Dictates Cancer Progression in the Prostate (2003) (707)
Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain (2004) (668)
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate (2009) (666)
Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis (1995) (661)
NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN (2007) (657)
ceRNA cross-talk in cancer: when ce-bling rivalries go awry. (2013) (638)
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. (2009) (631)
Pml is essential for multiple apoptotic pathways (1998) (612)
The transcriptional role of PML and the nuclear body (2000) (612)
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis (2004) (598)
The Role of PML in Tumor Suppression (2002) (581)
Role of SUMO-1-modified PML in nuclear body formation. (2000) (580)
Role of nucleophosmin in embryonic development and tumorigenesis (2005) (565)
Subtle variations in Pten dose determine cancer susceptibility (2010) (560)
Impaired Fas response and autoimmunity in Pten+/- mice. (1999) (552)
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. (1998) (550)
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance (2012) (549)
The BTB–zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions (2008) (540)
Targeted disruption of the housekeeping gene encoding glucose 6‐phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. (1995) (539)
Acute promyelocytic leukemia: from genetics to treatment. (1994) (537)
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. (2005) (529)
Role of PML in cell growth and the retinoic acid pathway. (1998) (525)
In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma (2011) (525)
Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL (1998) (521)
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse (2001) (513)
Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor α Degradation (2001) (509)
Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations (2016) (500)
The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network (2008) (480)
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. (2008) (478)
Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity (2015) (460)
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression (2010) (459)
The functions and regulation of the PTEN tumour suppressor: new modes and prospects (2018) (455)
The function of PML in p53-dependent apoptosis (2000) (453)
A continuum model for tumour suppression (2011) (453)
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. (2009) (451)
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response (2012) (439)
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. (2002) (436)
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. (2009) (433)
MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling (2013) (426)
Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27Kip1 Activity (1999) (426)
mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide (2016) (418)
Identification of the miR-106b~25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation (2010) (417)
The mechanisms of PML-nuclear body formation. (2006) (414)
Pro-senescence therapy for cancer treatment (2011) (412)
Identification of a tumour suppressor network opposing nuclear Akt function (2006) (411)
Dyskeratosis Congenita and Cancer in Mice Deficient in Ribosomal RNA Modification (2003) (411)
Regulation of p53 activity in nuclear bodies by a specific PML isoform (2000) (410)
Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. (2014) (386)
PML Regulates Apoptosis at Endoplasmic Reticulum by Modulating Calcium Release (2010) (384)
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. (2012) (381)
Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. (2007) (379)
Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent Manner (2011) (360)
PML regulates p53 stability by sequestering Mdm2 to the nucleolus (2004) (359)
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation (2008) (349)
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression (2005) (345)
Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State (2012) (345)
Loss of the tumor suppressor PML in human cancers of multiple histologic origins. (2004) (338)
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction (2009) (331)
PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR (2006) (327)
PML is a direct p53 target that modulates p53 effector functions. (2004) (326)
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. (2010) (326)
Acute leukemia with promyelocytic features in PML/RARα transgenic mice (1997) (323)
Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. (1991) (317)
A Novel Signal Transduction Cascade Involving Direct Physical Interaction of the Renin/Prorenin Receptor With the Transcription Factor Promyelocytic Zinc Finger Protein (2006) (306)
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence (2010) (305)
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus (2014) (301)
Activation of Akt/Protein Kinase B Overcomes a G2/M Cell Cycle Checkpoint Induced by DNA Damage (2002) (300)
A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor (2006) (298)
Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments (2013) (296)
The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo (2015) (286)
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. (2013) (284)
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. (2001) (283)
Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia. (1992) (281)
Cytoplasmic PML function in TGF-β signalling (2004) (280)
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. (2014) (280)
Plzf regulates limb and axial skeletal patterning (2000) (278)
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas (2007) (276)
The t(8;21) fusion protein, AML1–ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia (2002) (267)
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. (2003) (266)
Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. (1991) (260)
The acute promyelocytic leukaemia-associated PML gene is induced by interferon. (1995) (259)
Promyelocytic Leukemia Protein (Pml) and Daxx Participate in a Novel Nuclear Pathway for Apoptosis (2000) (255)
Tsc2-Rheb Signaling Regulates EphA-Mediated Axon Guidance (2009) (254)
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. (2006) (248)
Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia (1992) (246)
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. (1998) (244)
p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner (2015) (244)
A role for PML and the nuclear body in genomic stability (1999) (243)
TCR-inducible PLZF transcription factor required for innate phenotype of a subset of γδ T cells with restricted TCR diversity (2009) (242)
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. (2008) (242)
A metabolic prosurvival role for PML in breast cancer. (2012) (233)
Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function (2014) (231)
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. (1998) (230)
PTEN level in tumor suppression: how much is too little? (2011) (229)
Plzf Regulates Germline Progenitor Self-Renewal by Opposing mTORC1 (2010) (226)
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB (2009) (222)
Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. (2011) (218)
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. (2006) (214)
Regulation of B Versus T Lymphoid Lineage Fate Decision by the Proto-Oncogene LRF (2007) (212)
Identification of PTEN at the ER and MAMs and its regulation of Ca2+ signaling and apoptosis in a protein phosphatase-dependent manner (2013) (211)
Role of PML and the PML-nuclear body in the control of programmed cell death (2003) (209)
The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. (2002) (208)
PML targeting eradicates quiescent leukaemia-initiating cells (2008) (208)
An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance (2018) (208)
Transcriptional Repression of Stat6-Dependent Interleukin-4-Induced Genes by BCL-6: Specific Regulation of Iɛ Transcription and Immunoglobulin E Switching (1999) (207)
Nucleophosmin Serves as a Rate-Limiting Nuclear Export Chaperone for the Mammalian Ribosome (2008) (206)
Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis (2010) (206)
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias (1990) (205)
Characterization, Cryopreservation, and Ablation of Spermatogonial Stem Cells in Adult Rhesus Macaques (2007) (205)
Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. (2013) (204)
Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. (2002) (204)
Promyelocytic Leukemia Protein Mediates Interferon-Based Anti-Herpes Simplex Virus 1 Effects (2003) (201)
mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. (2005) (201)
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer (2015) (199)
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer (2018) (195)
Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. (1992) (191)
Polycystin-1 Regulates Extracellular Signal-Regulated Kinase-Dependent Phosphorylation of Tuberin To Control Cell Size through mTOR and Its Downstream Effectors S6K and 4EBP1 (2009) (189)
Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway (2019) (188)
Cytoplasmic PML function in TGF-beta signalling. (2004) (188)
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. (2000) (187)
PML mediates the interferon‐induced antiviral state against a complex retrovirus via its association with the viral transactivator (2001) (186)
BCL-6 regulates chemokine gene transcription in macrophages (2000) (186)
Acetylation-Dependent Regulation of Skp2 Function (2012) (183)
Role of GITR in activation response of T lymphocytes. (2002) (183)
Repression of kit Expression by Plzf in Germ Cells (2007) (181)
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. (2017) (181)
Signaling control of mRNA translation in cancer pathogenesis (2004) (180)
SUMO-1 protease-1 regulates gene transcription through PML. (2002) (179)
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. (2014) (176)
The chromosome make-up of mouse embryonic stem cells is predictive of somatic and germ cell chimaerism (2004) (175)
Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy (2009) (172)
Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. (1992) (170)
Plzf mediates transcriptional repression of HoxD gene expression through chromatin remodeling. (2002) (169)
Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies (2002) (163)
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. (1997) (162)
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. (2015) (161)
Breast cancer--loss of PTEN predicts resistance to treatment. (2004) (161)
Ubiquitination of K-Ras Enhances Activation and Facilitates Binding to Select Downstream Effectors (2011) (159)
Functional antagonism between Sall4 and Plzf defines germline progenitors. (2012) (154)
Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses (2020) (154)
The TLX1 oncogene drives aneuploidy in T-cell transformation (2010) (153)
In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma (2011) (151)
Development of Promyelocytic Zinc Finger and ThPOK-Expressing Innate γδ T Cells Is Controlled by Strength of TCR Signaling and Id3 (2009) (150)
Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression (2001) (149)
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence (2010) (147)
Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations (2016) (144)
Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. (1992) (142)
Regulation of apoptosis by PML and the PML-NBs (2008) (140)
Maternally transmitted severe glucose 6‐phosphate dehydrogenase deficiency is an embryonic lethal (2002) (140)
Two critical hits for promyelocytic leukemia. (2000) (140)
Mzf1 controls cell proliferation and tumorigenesis. (2001) (139)
A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. (1996) (139)
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. (2007) (138)
Molecular Cloning and Characterization of p56 dok-2 Defines a New Family of RasGAP-binding Proteins* (1998) (138)
A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARα and T18 oncoproteins (1999) (138)
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2013) (135)
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. (1993) (134)
Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. (1997) (133)
The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation* (2003) (132)
Role of PML and PML-RARα in Mad-Mediated Transcriptional Repression (2001) (130)
Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes (2008) (130)
PTEN in Neural Precursor Cells: Regulation of Migration, Apoptosis, and Proliferation (2002) (128)
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. (2008) (128)
Ubiquitin-dependent Degradation of p73 Is Inhibited by PML (2004) (128)
Lrf suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion (2013) (128)
Haplo‐insufficiency: a driving force in cancer (2011) (125)
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. (2008) (125)
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. (1997) (124)
Regulation of Pax3 transcriptional activity by SUMO-1-modified PML (2001) (123)
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia (2013) (122)
The theory of APL (2001) (121)
The APL paradigm and the "co-clinical trial" project. (2011) (120)
Effects of Promyelocytic Leukemia Protein on Virus-Host Balance (2002) (119)
GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease (2004) (119)
Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. (2001) (118)
The Epitranscriptome of Noncoding RNAs in Cancer. (2017) (116)
The Mechanisms of PML-Nuclear Body Formation. (2006) (116)
PTEN and TNF-α regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-κB-dependent pathway (2002) (116)
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms (2018) (114)
In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications (1999) (113)
Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. (2005) (113)
Evidence for BLM and Topoisomerase IIIα interaction in genomic stability (2001) (112)
Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. (1999) (112)
Identification of DOK genes as lung tumor suppressors (2010) (111)
RAR-alpha gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. (1991) (110)
PTEN ceRNA networks in human cancer. (2015) (110)
From pseudo-ceRNAs to circ-ceRNAs: a tale of cross-talk and competition (2013) (109)
PTEN and p53: who will get the upper hand? (2003) (109)
Co-aggregation of FcγRII with FcϵRI on Human Mast Cells Inhibits Antigen-induced Secretion and Involves SHIP-Grb2-Dok Complexes* (2004) (107)
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. (2017) (105)
LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. (2009) (105)
Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2019) (104)
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome (2006) (104)
PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development (2016) (103)
Role of Dok-1 and Dok-2 in Leukemia Suppression (2004) (102)
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2. (2016) (101)
P62dok, a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210bcr-abl (2001) (101)
TSPYL5 suppresses p53 levels and function by physical interaction with USP7 (2011) (100)
Dyskerin expression influences the level of ribosomal RNA pseudo‐uridylation and telomerase RNA component in human breast cancer (2006) (100)
Mouse hospital and co-clinical trial project—from bench to bedside (2015) (99)
CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection (2010) (99)
Mitochondrial Basis for Immune Deficiency: Evidence from Purine Nucleoside Phosphorylase–Deficient Mice (2000) (97)
Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. (2017) (94)
Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. (2005) (94)
The transcription factor Pokemon: a new key player in cancer pathogenesis. (2005) (94)
Gli3 and Plzf cooperate in proximal limb patterning at early stages of limb development (2005) (93)
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway (2004) (93)
In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. (2015) (93)
EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. (2009) (90)
Role of the Promyelocytic Leukemia Protein PML in the Interferon Sensitivity of Lymphocytic Choriomeningitis Virus (2001) (89)
Downstream of Kinase, p62dok, Is a Mediator of FcγRIIB Inhibition of FcεRI Signaling1 (2002) (89)
PTEN mediates Notch-dependent stalk cell arrest in angiogenesis (2015) (88)
Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms (2002) (88)
The role of PML in the control of apoptotic cell fate: a new key player at ER–mitochondria sites (2011) (87)
Promyelocytic Leukemia Zinc Finger Protein Regulates Interferon-Mediated Innate Immunity (2009) (87)
Changing venues for tumour suppression: balancing destruction and localization by monoubiquitylation (2007) (87)
Transcription therapy for cancer (2001) (87)
Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling (2014) (86)
c-Abl phosphorylates Dok1 to promote filopodia during cell spreading (2004) (86)
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. (2010) (85)
Pseudogenes in Human Cancer (2015) (85)
The Proto-Oncogene LRF Is under Post-Transcriptional Control of MiR-20a: Implications for Senescence (2008) (83)
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors (2008) (83)
Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1 (2001) (82)
PML Activates Transcription by Protecting HIPK2 and p300 from SCFFbx3-Mediated Degradation (2008) (81)
Histone deacetylases and transcriptional therapy with their inhibitors (2001) (80)
Akt methylation by SETDB1 promotes Akt kinase activity and oncogenic functions (2018) (80)
Promyelocytic Leukemia Protein Sensitizes Tumor Necrosis Factor α-Induced Apoptosis by Inhibiting the NF-κB Survival Pathway* (2003) (80)
As2O3 Enhances Retroviral Reverse Transcription and Counteracts Ref1 Antiviral Activity (2003) (79)
Molecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia. (1991) (79)
PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. (2002) (78)
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis (2009) (78)
Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age (2004) (77)
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. (2014) (77)
Stromal cell-derived factor-1alpha/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. (2005) (77)
Assessing the construct validity of the Italian version of the EQ-5D: preliminary results from a cross-sectional study in North Italy (2006) (76)
The deficiency of Akt1 is sufficient to suppress tumor development in Pten mice (2006) (75)
Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15;17) translocation. (1992) (75)
Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program (2019) (75)
Mouse models for multistep tumorigenesis. (2001) (74)
Phosphoinositide 3-Kinase–Dependent Membrane Recruitment of P62dok Is Essential for Its Negative Effect on Mitogen-Activated Protein (Map) Kinase Activation (2001) (72)
G-protein-coupled receptors regulate autophagy by ZBTB16-mediated ubiquitination and proteasomal degradation of Atg14L (2015) (70)
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long- term remission (1993) (70)
Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. (2004) (70)
Germline NPM1 mutations lead to altered rRNA 2’-O-methylation and cause dyskeratosis congenita (2019) (68)
Differential p53-Independent Outcomes of p19Arf Loss in Oncogenesis (2009) (68)
Fes-Cre Targets Phosphatidylinositol Glycan Class a (Piga) Inactivation to Hematopoietic Stem Cells in the Bone Marrow (2001) (67)
Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line. (1996) (67)
NGF-promoted axon growth and target innervation requires GITRL-GITR signaling (2008) (67)
Regulation of the p73 protein stability and degradation. (2005) (67)
In vivo analysis of the molecular genetics of acute promyelocytic leukemia (2001) (66)
Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. (2016) (65)
Noncoding RNAs and Cancer (2013) (65)
The puzzling multiple lives of PML and its role in the genesis of cancer. (2000) (65)
Mouse Modeling in Oncologic Preclinical and Translational Research (2006) (64)
Downstream of Tyrosine Kinases-1 and Src Homology 2-Containing Inositol 5′-Phosphatase Are Required for Regulation of CD4+CD25+ T Cell Development1 (2006) (64)
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP (2014) (63)
PML/RAR‐α rearrangement in acute promyelocytic leukaemias apparently lacking the t(15;17) translocation (1992) (62)
Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. (2001) (60)
Molecular genetics of acute lymphoblastic leukemia. (2009) (60)
Amplification of the Angiogenic Signal through the Activation of the TSC/mTOR/HIF Axis by the KSHV vGPCR in Kaposi's Sarcoma (2011) (58)
Role of LRF/Pokemon in lineage fate decisions. (2013) (58)
Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones (2017) (58)
The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. (2005) (58)
NPM mutations in acute myelogenous leukemia. (2005) (58)
CIP2A Promotes Proliferation of Spermatogonial Progenitor Cells and Spermatogenesis in Mice (2012) (57)
Disruption of PLZP in Mice Leads to Increased T-Lymphocyte Proliferation, Cytokine Production, and Altered Hematopoietic Stem Cell Homeostasis (2004) (57)
The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies. (2002) (57)
Promyelocytic Leukemia Activates Chk2 by Mediating Chk2 Autophosphorylation* (2006) (57)
Essential Role of the p110β Subunit of Phosphoinositide 3-OH Kinase in Male Fertility (2010) (57)
miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells (2019) (57)
A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. (2009) (56)
Akt Phosphorylates the Transcriptional Repressor Bmi1 to Block Its Effects on the Tumor-Suppressing Ink4a-Arf Locus (2012) (56)
Inhibition of cell proliferation by the interferon-inducible 204 gene, a member of the Ifi 200 cluster (1998) (56)
A Unified Nomenclature and Amino Acid Numbering for Human PTEN (2014) (55)
Evidence for BLM and Topoisomerase IIIalpha interaction in genomic stability. (2001) (55)
Developmental analysis of murine Promyelocyte Leukemia Zinc Finger (PLZF) gene expression: implications for the neuromeric model of the forebrain organization (1995) (54)
Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. (2010) (54)
Dok-1 Independently Attenuates Ras/Mitogen-Activated Protein Kinase and Src/c-Myc Pathways To Inhibit Platelet-Derived Growth Factor-Induced Mitogenesis (2006) (54)
RARα-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia (2007) (54)
Mx1 GTPase accumulates in distinct nuclear domains and inhibits influenza A virus in cells that lack promyelocytic leukaemia protein nuclear bodies. (2004) (54)
Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. (2014) (53)
E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. (2012) (53)
Modelling haematopoietic malignancies in the mouse and therapeutical implications (2002) (53)
PML-RARα Alleviates the Transcriptional Repression Mediated by Tumor Suppressor Rb* (2001) (53)
Distinct germline progenitor subsets defined through Tsc2–mTORC1 signaling (2015) (53)
The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence (2007) (52)
Functional Connection between Rad51 and PML in Homology-Directed Repair (2011) (50)
Promyelocytic Leukemia Protein 4 Induces Apoptosis by Inhibition of Survivin Expression* (2004) (50)
MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer (2017) (49)
PML, PLZF and NPM genes in the molecular pathogenesis of acute promyelocytic leukemia. (1996) (49)
The RNA-binding protein ESRP1 promotes human colorectal cancer progression (2016) (49)
The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor. (2001) (49)
Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway. (2003) (49)
The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. (2017) (49)
The theory of APL revisited. (2007) (48)
Characterization and analysis of the composition and dynamics of the mammalian riboproteome. (2013) (48)
PML interacts with Myc, and Myc target gene expression is altered in PML-null fibroblasts (2005) (48)
The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63 (2005) (48)
Downstream of kinase, p62(dok), is a mediator of Fc gamma IIB inhibition of Fc epsilon RI signaling. (2002) (47)
Rearrangements of the RAR‐α gene in acute promyelocytic leukaemia: (1991) (47)
The role of promyelocytic leukemia zinc finger and promyelocytic leukemia in leukemogenesis and development (2001) (47)
SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. (2019) (46)
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. (2013) (46)
Acetylation of PML Is Involved in Histone Deacetylase Inhibitor-mediated Apoptosis* (2008) (45)
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis (2014) (45)
Physical and functional link of the leukemia-associated factors AML1 and PML. (2005) (45)
ETS rearrangements and prostate cancer initiation (2009) (45)
Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs (2021) (45)
PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression (2019) (45)
ATR, PML, and CHK2 Play a Role in Arsenic Trioxide-induced Apoptosis* (2006) (45)
The nuclear bodies inside out: PML conquers the cytoplasm. (2011) (45)
BCR-mediated apoptosis associated with negative selection of immature B cells is selectively dependent on Pten (2009) (44)
In vivo analysis of the role of aberrant histone deacetylase recruitment and RARα blockade in the pathogenesis of acute promyelocytic leukemia (2006) (44)
Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy (2009) (44)
Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia (2013) (44)
Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders? (2002) (43)
Gene rearrangements in the molecular pathogenesis of acute promyelocytic leukemia (1997) (43)
PML-Retinoic Acid Receptor α Inhibits PML IV Enhancement of PU.1-Induced C/EBPε Expression in Myeloid Differentiation (2007) (43)
The nucleolus: at the stem of immortality (2003) (43)
p18Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control (2006) (43)
CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor (2008) (43)
Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARα (2004) (43)
PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage. (2019) (43)
Quantification of PML‐RARα transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT‐PCR for the detection of minimal residual disease and induction of the leukaemia‐specific mRNA by alpha interferon (1996) (42)
A Role for PML in Innate Immunity. (2011) (42)
Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor. (2012) (42)
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. (1993) (42)
Aberrant ceRNA activity drives lung cancer (2014) (42)
Mitochondria associated membranes (MAMs) as critical hubs for apoptosis (2011) (41)
LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control (2020) (40)
Cyclin-dependent kinase antagonizes promyelocytic leukemia zinc-finger through phosphorylation (2008) (40)
Leukemia with distinct phenotypes in transgenic mice expressing PML/RARα, PLZF/RARα or NPM/RARα (2006) (40)
The promyelocytic leukemia protein functions as a negative regulator of IFN-γ signaling (2006) (40)
Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: from molecular biology to clinical applications. (1998) (39)
The Tug1 lncRNA locus is essential for male fertility (2020) (39)
ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM (2015) (39)
The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. (2006) (39)
ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence (2013) (39)
Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. (2006) (38)
The PTEN – PI 3 K Axis in Cancer (2019) (38)
PTEN Is a Negative Regulator of NK Cell Cytolytic Function (2015) (37)
A circular twist on microRNA regulation (2017) (37)
Promyelocytic Leukemia Zinc Finger Protein Activates GATA4 Transcription and Mediates Cardiac Hypertrophic Signaling from Angiotensin II Receptor 2 (2012) (37)
Faithfull modeling of PTEN loss driven diseases in the mouse. (2010) (37)
Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. (1994) (37)
The RNA Binding Protein ESRP1 Fine-Tunes the Expression of Pluripotency-Related Factors in Mouse Embryonic Stem Cells (2013) (36)
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (36)
Gata3 antagonizes cancer progression in Pten-deficient prostates. (2013) (36)
Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence (2012) (36)
HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse (2014) (36)
Active Pin 1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer (2015) (35)
The Effect of Deleting p110δ on the Phenotype and Function of PTEN-Deficient B Cells1 (2008) (35)
Glucocorticoid-induced Tumor Necrosis Factor Receptor Is a p21Cip1/WAF1 Transcriptional Target Conferring Resistance of Keratinocytes to UV Light-induced Apoptosis* (2005) (35)
p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. (2006) (35)
62 dok , a Negative Regulator of Ras and Mitogen-activated Protein Kinase ( MAPK ) Activity , Opposes Leukemogenesis by p 210 bcr-abl (2001) (34)
The function of PML in p 53-dependent apoptosis (2000) (34)
A co-clinical platform to accelerate cancer treatment optimization. (2015) (33)
Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation (2017) (33)
Giving blood: a new role for CD40 in tumorigenesis (2006) (33)
Dok1 and Dok2 proteins regulate natural killer cell development and function (2014) (33)
TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation (2015) (32)
Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism (2018) (32)
WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. (2020) (32)
Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. (2001) (32)
The Csk-Associated Adaptor PAG Inhibits Effector T Cell Activation in Cooperation with Phosphatase PTPN22 and Dok Adaptors. (2016) (31)
Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. (2014) (31)
Copper Promotes Tumorigenesis by Activating the PDK1‐AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner (2021) (30)
Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development (2012) (30)
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. (2014) (30)
Initiation of mRNA Translation in Oncogenesis: The Role of eIF4E (2004) (29)
BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation (2015) (29)
miR-22 in tumorigenesis (2013) (29)
Deregulated TGF-beta signaling in leukemogenesis. (2005) (29)
A focus on the spread of the delta variant of SARS-CoV-2 in India (2021) (29)
Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth (2016) (29)
Somatic human ZBTB7A zinc finger mutations promote cancer progression (2016) (28)
The PTEN Tumor Suppressor Forms Homodimers in Solution. (2015) (28)
Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model (2015) (28)
Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 Tax oncoprotein (2003) (27)
Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling. (2013) (26)
p27 deficiency desensitizes Rb−/− cells to signals that trigger apoptosis during pituitary tumor development (2003) (25)
Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner (2013) (25)
Breaking the rules of cancer (2006) (25)
PTEN induces apoptosis and cavitation via HIF-2-dependent Bnip3 upregulation during epithelial lumen formation (2014) (25)
Bone Marrow Endosteal Mesenchymal Progenitors Depend on HIF Factors for Maintenance and Regulation of Hematopoiesis (2014) (25)
Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. (2016) (25)
The functions and regulation of the PTEN tumour suppressor (2012) (25)
Morgana acts as an oncosuppressor in chronic myeloid leukemia. (2015) (24)
Targeting aberrant transcriptional repression in acute myeloid leukemia. (2003) (24)
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. (2015) (24)
Causality and Chance in the Development of Cancer. (2015) (24)
The Tumor Suppressor PML Specifically Accumulates at RPA/Rad51-Containing DNA Damage Repair Foci but Is Nonessential for DNA Damage-Induced Fibroblast Senescence (2014) (24)
Inhibition of HECT E3 ligases as potential therapy for COVID-19 (2021) (24)
Generation of functional hepatocytes from mouse germ line cell-derived pluripotent stem cells in vitro. (2010) (24)
Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival (2018) (24)
Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. (2017) (23)
Causality and Chance in the Development of Cancer. (2015) (23)
Morgana acts as a proto‐oncogene through inhibition of a ROCK–PTEN pathway (2014) (23)
Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. (2011) (23)
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity (2016) (23)
Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling (2019) (23)
The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer (2018) (22)
Prostate Cancer Progression (2010) (22)
DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma (2013) (22)
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy (2019) (22)
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy (2019) (22)
Pml represses tumour progression through inhibition of mTOR (2011) (21)
Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo (2002) (21)
A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche (2018) (21)
SPAR, a lncRNA encoded mTORC1 inhibitor (2017) (21)
The pleiotropic role of non-coding genes in development and cancer. (2016) (20)
CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor (2009) (20)
Deregulated TGF-β signaling in leukemogenesis (2005) (20)
Co‐inhibitory roles for glucocorticoid‐induced TNF receptor in CD1d‐dependent natural killer T cells (2008) (20)
Of model pets and cancer models: an introduction to mouse models of cancer. (2014) (19)
Downstream of Kinase, p62, Is a Mediator of Fc RIIB Inhibition of Fc RI Signaling (2002) (19)
Pseudogenes as competitive endogenous RNAs: target prediction and validation. (2014) (19)
Summary Sox 2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain (2004) (19)
The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care (2018) (19)
Cellular senescence as a possible mechanism for halting progression of keloid lesions. (2011) (19)
"Snorkeling" for missing players in cancer. (2012) (18)
Modeling acute promyelocytic leukemia in the mouse: new insights in the pathogenesis of human leukemias. (2001) (18)
p53 de-ubiquitination: at the edge between life and death (2002) (18)
Transcriptional regulation of cellular transformation (2000) (18)
Up-regulation of Translation Eukaryotic Initiation Factor 4E in Nucleophosmin 1 Haploinsufficient Cells Results in Changes in CCAAT Enhancer-binding Protein α Activity (2012) (17)
Identification of competing endogenous RNAs of the tumor suppressor gene PTEN: A probabilistic approach (2017) (17)
Structural and functional organization of the HF.10 human zinc finger gene (ZNF35) located on chromosome 3p21-p22. (1992) (16)
Nuclear Akt2 Opposes Limbal Keratinocyte Stem Cell Self‐Renewal by Repressing a FOXO‐mTORC1 Signaling Pathway (2014) (16)
Dok1 and SHIP Act as Negative Regulators of v-Abl-Induced Pre-B Cell Transformation, Proliferation and Ras/Erk Activation (2005) (16)
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells. (2015) (16)
Rearrangements of the RAR-alpha gene in acute promyelocytic leukaemia: correlations with morphology and immunophenotype. (1991) (15)
Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML) (2014) (15)
LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair (2015) (15)
SnapShot: PTEN Signaling Pathways (2008) (15)
Dok1 and Dok2 Proteins Regulate Cell Cycle in Hematopoietic Stem and Progenitor Cells (2016) (14)
4-Oxoretinol, a metabolite of retinol in the human promyelocytic leukemia cell line NB4, induces cell growth arrest and granulocytic differentiation. (1998) (14)
Target competition: transcription factors enter the limelight (2014) (14)
The PML-nuclear body associated protein Daxx regulates the cellular response to CD40 (2006) (14)
Suppression of T-cell lymphomagenesis in mice requires PTEN phosphatase activity. (2015) (14)
Preferential expression of the transcription coactivator HTIF1α gene in acute myeloid leukemia and MDS-related AML (2002) (14)
Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells (2020) (14)
Found in translation of mTOR signaling (2012) (13)
MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia (2014) (13)
Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis (2018) (13)
Loss of LDAH associated with prostate cancer and hearing loss (2018) (13)
Molecular genetics of the t(15;17) of acute promyelocytic leukemia (APPL). (1992) (13)
Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations (2021) (13)
Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis (2019) (12)
Effective utilization and appropriate selection of genetically engineered mouse models for translational integration of mouse and human trials. (2013) (12)
The mitochondrial Italian Human Proteome Project initiative (mt-HPP). (2013) (12)
Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids (2022) (12)
Endosome and INPP4B (2015) (12)
β-tting on p63 as a Metastatic Suppressor (2009) (12)
Erratum: Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy (Cell Death and Differentiation (2009) vol. 16 (1018-1029) 10.1038/cdd.20089.46) (2009) (12)
Pills of PTEN? In and out for tumor suppression (2013) (11)
Establishment of a Humanized APL Model via the Transplantation of PML-RARA-Transduced Human Common Myeloid Progenitors into Immunodeficient Mice (2014) (11)
The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth (2018) (11)
The Lilliputians and the Giant: An Emerging Oncogenic microRNA Network that Suppresses the PTEN Tumor Suppressor In Vivo. (2013) (11)
Regulation of NF-κB by PML and PML-RARα (2017) (11)
The Promyelocytic Leukemia Protein Is Upregulated in Conditions of Obesity and Liver Steatosis (2015) (11)
Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML. (2021) (11)
Loss of Wave1 gene defines a subtype of lethal prostate cancer (2015) (10)
The RNA-binding protein ESRP 1 promotes human colorectal cancer progression (2017) (10)
The myeloperoxidase gene in acute promyelocytic leukemia (1989) (10)
Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. (1994) (9)
Shape-shifting and tumor suppression by PLZF (2010) (9)
PTEN Mouse Models of Cancer Initiation and Progression. (2019) (9)
Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis (2011) (9)
The function of PML in p53-dependent (2000) (9)
Tumor microenvironment revisited (2014) (9)
ZBTB7A governs estrogen receptor alpha expression in breast cancer (2018) (9)
Erratum: Identification of the miR-106b-25 micro RNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation (Science Signaling (2010) 3 (er6)) (2010) (9)
PTENP1 is a ceRNA for PTEN: it’s CRISPR clear (2020) (9)
Dok-1 negatively regulates platelet integrin αIIbβ3 outside-in signalling and inhibits thrombosis in mice (2016) (9)
Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma (2021) (8)
P-TEN exciting years: from the cytosol to the nucleus and back to keep cancer at bay (2008) (8)
Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying essential circRNAs (2020) (8)
NPM-MLF1 synergizes with Npm haploinsufficiency to enhance myeloid progenitor activity (2012) (8)
Molecular Cloning and Characterization of p56 Defines a New Family of RasGAP-binding Proteins* (1998) (8)
Human CD 4 Lymphocytes Specifically Recognize a Peptide Representing the Fusion Region of the Hybrid Protein pml / RARa Present in Acute Promyelocytic Leukemia Cells (2003) (7)
Germline Modification Strategies (2004) (7)
Elucidating the Oncogenic Potential of NPMc+ In Vitro and In Vivo. (2006) (7)
A Dialog on the First 20 Years of PML Research and the Next 20 Ahead (2014) (7)
Acute promyelocytic leukemia : molecular genetics, mouse models and targeted therapy (2006) (6)
Mitochondrial Basis for Immune Deficiency (2000) (6)
Genetic fusions favor tumorigenesis through degron loss in oncogenes (2021) (6)
Critical role of Dok-1 and Dok-2 in leukemia suppression (2004) (6)
Dok‐1 overexpression promotes development of γδ natural killer T cells (2012) (6)
Stromal cell – derived factor-1 / CXCL 12 – induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p 62 Dok-1 (2004) (6)
Dual DNA and protein tagging of open chromatin unveils dynamics of epigenomic landscapes in leukemia (2021) (6)
Knocking in and out genes and trans genes: the use of the engineered mouse to study normal and aberrant hemopoiesis. (1998) (6)
Peptide Platform as a Powerful Tool in the Fight against COVID-19 (2021) (6)
3-Kinase–dependent Membrane Recruitment of p62 dok Is Essential for Its Negative Effect on Mitogen-activated Protein (MAP) Kinase (2001) (6)
The HECT family of E3 ubiquitin ligases and PTEN. (2021) (6)
Utility of LRF/Pokemon and NOTCH1 Protein Expression in the Distinction Between Nodular Lymphocyte-Predominant Hodgkin Lymphoma and Classical Hodgkin Lymphoma (2014) (6)
Two decades of cancer genetics: from specificity to pleiotropic networks. (2005) (5)
The Role of Nucleophosmin In Hematopoietic Stem Cells and the Pathogenesis of Myelodysplastic Syndrome (2010) (5)
MUC 1 IS A POTENTIAL TARGET FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA STEM CELLS (2014) (5)
Leukaemia: a genetic disorder of haemopoietic cells. (1993) (5)
Development of the Proximal-Anterior Skeletal Elements in the Mouse Hindlimb Is Regulated by a Transcriptional and Signaling Network Controlled by Sall4 (2020) (5)
Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia: a case report and review of the literature. (2002) (5)
Phosphatase-Independent Functions of the Tumor Suppressor PTEN (2016) (5)
The RNA Binding Protein ESRP 1 Fine-Tunes the Expression of Pluripotency-Related Factors in Mouse Embryonic Stem Cells (2013) (4)
Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition (2010) (4)
WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. (2021) (4)
Vulnerabilities of PTEN – TP 53-Defi cient Prostate Cancers to Compound PARP – PI 3 K Inhibition (2019) (4)
Cytoplasmic PML Function in TGF-β Signaling. (2004) (4)
Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML (2020) (4)
Atheroma development in apolipoprotein E-null mice is not affected by partial inactivation of PTEN. (2006) (4)
Enhancing Chemotherapy Ef ficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity Graphical (2014) (4)
WWP1 germline variants are associated with normocephalic autism spectrum disorder (2020) (4)
Preclinical and Coclinical Studies in Prostate Cancer. (2018) (4)
Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. (2012) (4)
Physical and functional link of the leukemia-associated factors AML 1 and PML (2004) (3)
The myeloperoxidase gene in acute promyelocytic leukemia. (1989) (3)
111. Characterization of the acute promyelocytic leukemia (APL) specific t(15;17) PML-RARα chimeric product (1992) (3)
Erratum: CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor (Molecular Cellular Biochemistry (2008) vol. 316 (149-154) 10.1007/s11010-008-9812-7) (2009) (3)
Medicine: Taking apart a cancer protein (2003) (3)
Molecular Genetics of APL (2018) (3)
APL as a paradigm in biomedical research: a journey toward the cure. (2007) (3)
Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model (2010) (2)
The PTEN-PI3K Axis in Cancer (2019) (2)
p18 and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control (2006) (2)
hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression (2014) (2)
Cell Cycle Control Regulatory Loop between Cell Growth and Constrain a Positive Pten and Ink4c p18 (2014) (2)
Selection of a highly enriched population of retrovirus-infected human hematopoietic progenitor cells using SNL fibroblasts. (1995) (2)
Acetylation of PML Plays a Key Role in Histone Deacetylase Inhibitor-Mediated Apoptosis through Enhanced PML Sumoylation. (2007) (2)
INHIBITION OF USP7 INDUCES SELECTIVE CANCER CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PTEN AND INDEPENDENTLY FROM P53 STATUS (2016) (2)
Treatment with 5-azacytidine accelerates acute promyelocytic leukemia leukemogenesis in a transgenic mouse model. (2011) (2)
Endosome and INPP 4 B (2016) (2)
Corrigendum : Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation (2009) (2)
The promyelocytic leukemia protein, PML, localizes to the nucleolus after DNA damage, interacts with Mdm2 and promotes p53 stability. (2002) (2)
69 The ceRNA Hypothesis and the Non-coding Revolution in Cancer Research and Therapy (2012) (2)
The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA (2014) (2)
miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells (2019) (2)
Homology 2-Containing Inositol 5 Downstream of Tyrosine Kinases-1 and Src RothmanPier (2006) (1)
ABERRANT ERG EXPRESSION COOPERATES WITH PTEN LOSS TO PROMOTE PROSTATE TUMORIGENESIS (2008) (1)
PML ACTIVATES CHK2 BY MEDIATING CHK2 AUTOPHOSPHORYLATION (2006) (1)
Acute Promyelocytic Leukemia (2007) (1)
Nanoformulation of the PARP Inhibitor Olaparib Enables Radiosensitization of a Radiation-Resistant Prostate Cancer Model (2016) (1)
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2020) (1)
Mutations of the PML tumor suppressor gene in APL (2003) (1)
POKEMON Is a Proto-Oncogene Which Plays a Key Role in Lymphomagenesis. (2004) (1)
Therapeutics , Targets , and Chemical Biology Differential Expression of S 6 K 2 Dictates Tissue-Specific Requirement for S 6 K 1 in Mediating Aberrant mTORC 1 Signaling and Tumorigenesis (2011) (1)
Nucleophosmin Is Required for Macrophage Function and Maturation. (2009) (1)
Role of RAR alpha-PLZF in the pathogenesis of acute promyelocytic leukemia. (1998) (1)
Taking apart a cancer protein (2003) (1)
Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine (2012) (1)
Posttranscriptional Regulation of PTEN by Competing Endogenous RNAs. (2016) (1)
Indole-3-carbinol in vitro antiviral activity against SARS-Cov-2 virus and in vivo toxicity (2022) (1)
Secrets of a killer (2007) (1)
Dok 1 and Dok 2 proteins regulate natural killer cell development and function (2014) (1)
Nucleophosmin-1 Interacts with CCAAT Enhancer Binding Protein Alpha (C/EBPα) to Facilitate Granulocyte Maturation: Implications in MDS and AML. (2009) (1)
G-protein-coupled receptors regulate autophagy by ZBTB 16-mediated ubiquitination and proteasomal degradation of Atg 14 (2015) (1)
Twenty-first annual Pezcoller Symposium: Unconventional Therapeutic Targets in Cancer. (2010) (1)
Target competition: transcription factors enter the limelight (2014) (1)
Abstract B48: Prostate cancer pre-treatment with nanoformulated Olaparib overcomes radiation resistance (2017) (1)
Modeling Cancer-Associated Mutations of PTEN in Mice. (2016) (1)
In Vivo Silencing/Overexpression of lncRNAs by CRISPR/Cas System. (2021) (1)
Role of PML in p53-dependent apoptosis. (2000) (1)
leukemia in long- term remission detectable residual disease in patients with acute promyelocytic Absence of reverse transcription-polymerase chain reaction (2011) (0)
Abstract IA16: The ceRNA hypothesis and the non-coding revolution in cancer research and therapy (2012) (0)
21 Co-inhibitory Roles for Glucocorticoid-induced TNF Receptor (GITR) in CD1d-dependent Natural Killer T Cells (2007) (0)
Modeling leiomyosarcoma in the mouse (2006) (0)
110. Molecular genetics of the t(15;17) of acute promyelocytic leukemias (APL) (1992) (0)
PTEN PATHWAYS & TARGETS (2010) (0)
A Dual Proto-Oncogenic and Tumor Suppressive Role of LRF/POKEMON In Hemopoietic Malignancies through Control of Cell Fate Decision (2010) (0)
MUC1 Expression Is Essential For Establishment Of Acute Myeloid Leukemia In Vivo (2013) (0)
P-gp function and expression in decreased in hCG-PML-RAR'alfa' transgenic mice before the development of leukemia (2003) (0)
1 The PTEN-PI 3 K axis in cancer 2 (2019) (0)
A CK2-Dependent Mechanism for PML Degradation upon Cellular and Oncogenic Stress. (2006) (0)
CD8 T cells require intrinsic GITR signaling for their clonal expansion during influenza infection in vivo (2010) (0)
Upregulation of eIF4E in Nucleophosmin 1 (NPM1) Haploinsufficient Cells Alters CCAAT Enhancer Binding Protein Alpha (C/EBPα) Activity: Implications for MDS and AML (2011) (0)
LRF/Pokemon Plays a Pivotal Role in B Versus T Lymphoid Lineage Fate Decision at the Early Lymphoid Progenitor Stage by Opposing Notch1 Signaling. (2006) (0)
A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche (2018) (0)
Tumor Growth Carbon Monoxide Expedites Metabolic Exhaustion to Inhibit (2013) (0)
MouseModeling in Oncologic Preclinical andTranslational Research (2006) (0)
compound PARP / PI 3 K inhibition Vulnerabilities of PTEN-p 53-deficient prostate cancers to (2014) (0)
LOUP Mediates Opposing Regulatory Effects of RUNX 1 and RUNX 1-ETO in 1 t ( 8 ; 21 ) AML 2 (2020) (0)
A process for the preparation of arsentrioxidpræparater (1998) (0)
Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism (2018) (0)
Abstract IA3: The Co-Clinical Trial Project (2014) (0)
Therapeutic inhibition of HAUSP-PTEN network in chronic lymphocytic leukemia (2015) (0)
Pseudogenes as Competitive Endogenous RNAs: Target Prediction and Validation. (2021) (0)
Severe Influenza Infection Cell Clonal Expansion and Mouse Survival CD 8 T Cell-Intrinsic GITR Is Required for T (2010) (0)
Conditional Inactivation of the Proto-Oncogene Pokemon Results in Block of Differentiation in Multiple Hematopoietic Lineages. (2005) (0)
Corrigendum: Loss of LDAH associated with prostate cancer and hearing loss. (2019) (0)
Expression pattern of the RARcr-PML fusion gene in acute promyelocytic leukemia (0)
Identification of competing endogenous RNAs of the tumor suppressor gene PTEN: A probabilistic approach (2017) (0)
Gene Knockouts in Cancer Research (2007) (0)
present in acute promyelocytic leukemia cells representing the fusion region of the hybrid protein pml/RAR alpha Human CD4 lymphocytes specifically recognize a peptide (2011) (0)
Arrest and Granulocytic Differentiation Promyelocytic Leukemia Cell Line NB 4 , Induces Cell Growth 4-Oxoretinol , a Metabolite of Retinol in the Human Updated (2006) (0)
P11.46 Morgana overexpression confers resistance from apoptotic cell death (2011) (0)
Molecular Genetics of Acute Promyelocytic Leukemia: A Rationale for “Transcription Therapy” for Cancer (2000) (0)
Molecular genetics of the t(15;17) translocation in acute promyelocytic leukemia. (1993) (0)
Science Signaling Podcast: 03 February 2009 (2009) (0)
Altered Liver Regeneration after Partial Hepatectomy in Pml-Knockout Mice (2016) (0)
Biochemistry for tomorrow's medicine. Abstracts of the 36th FEBS Congress. Torino, Italy. June 25-30, 2011. (2011) (0)
265: A Constitutively Activated Mutant form of Propsa that Manifests Catalytic Action Increases Cell Invasion in Vitro and Frequency of Pulmonary Metastases in vivo in a Subcutaneous Mouse Xenograft Model (2007) (0)
In Vivo Analysis of the Role of C/EBPα in Acute Promyelocytic Leukemia Genesis. (2006) (0)
Abstract B06: Abi1 levels regulate prostate tumor progression in mice downstream from Pten inactivation (2014) (0)
Activation of the P38 MAPK Pathway Results in Ubiquitin-Proteasome Degradation of the PML Tumor Suppressor Protein. (2004) (0)
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy (2019) (0)
Hematopoietic p53 loss cell-extrinsically defines an immune infiltrated microenvironment in leukemia and pre-leukemia (2020) (0)
An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22 (2022) (0)
This information is current as in Hematopoietic Stem and Progenitor Cells Dok 1 and Dok 2 Proteins Regulate Cell Cycle (2016) (0)
PTEN in Immunity. (2022) (0)
SUMO modification of Huntingtin and disease pathology. (2004) (0)
PML enhances p73 transcriptional activity and biological functions by preventing its proteasome-dependent degradation (2002) (0)
Abstract 1694: CHIP and AML mutations dictate the composition of hematopoietic microenvironments (2020) (0)
Author Correction: Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate (2020) (0)
Macrophage Function is Regulated by NPM1-mediated 2’-O-methylation (2020) (0)
Resistance to Apoptosis and Cell Proliferation in the hCG-PMl-RARα Transgenic Mouse Model Are Age-Related. (2005) (0)
PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression (2019) (0)
Abstract 1403: Modeling of Abi1 loss using spheroid cultures to investigate mechanisms of prostate tumorigenesis (2018) (0)
miR-214 in stroma cells and tumor progression (2016) (0)
Stroma-derived miR-214 coordinates tumor dissemination (2023) (0)
PML Activates Transcription by Protecting HIPK2 and p300 from SCF Fbx3 -Mediated Degradation (cid:1) † (2008) (0)
Abstract 601: Essential role of LRF in mesenchymal stem cell differentiation and tumorigenesis through Dlk1 and Sox9 repression (2014) (0)
Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition (2012) (0)
Author Correction: Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2020) (0)
Mammalian Ribosome Nuclear Export Chaperone for the Nucleophosmin Serves as a Rate-Limiting (2014) (0)
Pharmacokinetics of arsenic trioxide in patients with acute promyelocytic leukemia (1999) (0)
Hematological Malignancies and Premalignant Conditions (2014) (0)
The role of GITR in the anti‐influenza CD8 memory T cell response (2008) (0)
Nuclear dynamics of PML for c-Jun transcriptional regulation in response to DNA damage. (2002) (0)
Development of the Proximal-Anterior Skeletal Elements in the Mouse Hindlimb Is Regulated by a Transcriptional and Signaling Network Controlled by Sall4. (2020) (0)
ESMO-EACR - Targeted therapies: Promises, successes and failures (2012) (0)
PML is required for the ability of DAXX to regulate programmed cell death. (1999) (0)
Transcriptional repression of the rara pathyway is crucial for leukemogenesis (2000) (0)
Gamma-delta T cells (WS-094) Chairpersons: Yoshimasa Tanaka, Marc Bonneville (2010) (0)
Abstract IA15: New insights on the role of tumor suppressor phosphatases (2015) (0)
Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer (2012) (0)
The Pokemon/LRF-Notch Paradigm. (2008) (0)
PTEN and MDM2 inhibitors: Toward a novel pro-senescence therapy approach for patients with cancer. (2010) (0)
Role of p65(dok) in leukemogenesis by p210(bcr-abl) (2000) (0)
Phenotype and Function of PTEN-Deficient on the δ The Effect of Deleting p110 (2017) (0)
Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (0)
Cytolytic Function PTEN Is a Negative Regulator of NK Cell (2015) (0)
81 Proffered Paper: Regulation of Cellular Metabolism by Cancer Genes – Implications in Breast Cancer (2012) (0)
and Controlled by Strength of TCR Signaling T Cells Is d g and ThPOK-Expressing Innate Development of Promyelocytic Zinc Finger (2009) (0)
Role of NPM in the Control of Genetic Stability and Tumorigenesis. (2005) (0)
Synthetic Methodologies and Therapeutic Potential of Indole-3-Carbinol (I3C) and Its Derivatives (2023) (0)
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2020) (0)
Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (0)
PML modulates p73-dependent transcription and apoptosis. (2001) (0)
The ceRNA world: a new way of looking at the role of different RNA molecules (2012) (0)
BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia (2010) (0)
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer (2018) (0)
AWARD NUMBER: W81XWH-14-1-0590 TITLE: “A Riboproteomic Platform to Identify Novel Targets for Prostate Cancer Therapy” PRINCIPAL INVESTIGATOR: Dr. Pier Paolo Pandolfi de Rinaldis CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center (2015) (0)
WWP 1 inactivation enhances efficacy of PI 3 K inhibitors while suppressing their toxicities in breast cancer models (2021) (0)
Two's Company, Three's a Crowd: Rb1/Trp53/Pten Trifecta and Lung Cancer Molecular and Histopathologic Heterogeneity. (2023) (0)
A Riboproteomic Platform to Identify Novel Targets for Prostate Cancer Therapy (2015) (0)
In Vivo Analysis of PML-RARA in a Humanized Mouse Model (2014) (0)
LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control (2020) (0)
ceRNAs and ceRNA Networks in Normal and Malignant Hematopoiesis and Their Therapeutic Implications (2013) (0)
P-118 Pilot trial of the histone deacetylase inhibitor depsipeptide in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) (2005) (0)
700 T cell heterogeneity in patients with common variable immunodeficiency (CVI) as assessed by T cell receptor (TCR) gene analysis and evaluation of T cell subpopulations (1991) (0)
Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2019) (0)
CD8 T cells require intrinsic GITR signaling for their clonal expansion during influenza infection in vivo (50.21) (2010) (0)
PML Controls PTEN Localization and Function in APL through a Novel Deubiquitination Pathway (2008) (0)
663: XPD (ERCC-2) and Prostate Cancer: Susceptibility Depends on the Degree of DNA Damage and Transcriptional Interference (2007) (0)
Huntingtin is SUMO-1 Modified: Implications for Huntington's Disease Pathogenesis (2004) (0)
MURINE MODELS OF APL INDUCED BY CO-EXPRESSION OF THE PML-RARα FUSION WITH EITHER FLT3-ITD OR ONCOGENIC K-RAS ALLELES (2005) (0)
Role of Daxx in B cell selection and apoptosis by CD40. (2000) (0)
Generation of a Factor Dependent Myeloid Cell Line from Nucleophosmin-1 Heterozygous (NPM-1+/−) Mouse Bone Marrow as a Model for 5q- MDS (2008) (0)
27A Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer (2010) (0)
S4. Neurotrophic factors in autonomic nervous system development S4.1 Novel regulators of sympathetic innervation in the developing mouse (2009) (0)
AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions (2019) (0)
Author Correction: Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle (2020) (0)
Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs (2021) (0)
Metabolic Sensor, PPARA, Regulates Differentiation and Immune Response in AML (2021) (0)
Abstract IA12: The noncoding RNA revolution in cancer research (2013) (0)
Author Correction: Intragenic antagonistic roles of protein and circRNA in tumorigenesis (2020) (0)
Abstract C112: Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity (2015) (0)
Aberrant rRNA 2'-O-Methylation Causes Bone Marrow Failure and Defective Immune Function (2020) (0)
Dosage and tumour suppression (2012) (0)
Table of Contents (1995) (0)
Abstract 4979: Cabozantinib eradicates advanced murine prostate cancer by activating neutrophil-mediated anti-tumor innate immunity (2016) (0)
Tokuda Akihiro Tomida Shinya Toyokuni Hitoshi Tsuda Shoichiro Tsugane Tatsuhiko Tsunoda Heiichiro Udono Koji Ueda Yoshimasa Uehara Hiroo Ueno Kazuo Umezawa Toshikazu Ushijima Toshihiko Wakabayashi Kenji Wakai Tetsuro Watabe (2016) (0)
Abstract A37: The BRAF pseudogene is a proto-oncogenic competitive endogenous RNA. (2015) (0)
Deacetylase Inhibitor-mediated Apoptosis Acetylation of PML Is Involved in Histone Modification , and Degradation : Protein Synthesis , Post-Translational (2008) (0)
Analyses of Pokemon Protein Expression in Lymphoma Reveals Elevated Expression in Nodular Lymphocyte Predominant Hodgkin Lymphoma Compared to Classical Hodgkin Lymphoma. (2005) (0)
Mice with hematopoiesis deficient in glycosyl phosphatidylinositol (GPI) linked molecules: A possible model for paroxysmal nocturnal hemoglobinuria(PNH) (1996) (0)
Akt-Mediated Phosphorylation of Bmi1 Regulates Its Chromatin Association and Growth Promoting Properties. (2009) (0)
The ceRNA hypothesis , the non-coding revolution and the future of cancer research and its therapy (2011) (0)

This paper list is powered by the following services:

Other Resources About Pier Paolo Pandolfi

What Schools Are Affiliated With Pier Paolo Pandolfi?

Pier Paolo Pandolfi is affiliated with the following schools:

Pier Paolo Pandolfi's Academic­Influence.com Rankings